Showing 3741-3750 of 9072 results for "".
- AI Model Accurately Scores Psoriasis Severity from Clinical Imageshttps://practicaldermatology.com/news/ai-model-accurately-scores-psoriasis-severity-from-clinical-images/2484588/A new study demonstrates the potential of artificial intelligence (AI) to improve the consistency and objectivity of psoriasis severity assessments based on 2D clinical images. Researchers for the study used the YOLOv8 deep lear
- Skin of Color Society Media Day Analyzes Latest Trendshttps://practicaldermatology.com/news/skin-of-color-society-media-day-analyzes-latest-trends/2484533/In an era of misinformation and viral skincare fads, the Skin of Color Society’s (SOCS) 8th Annual Media Day offered a timely and authoritative voice, gathering top board-certified dermatologists to address critical dermatologic topics relevant to patients with skin of color. From trending TikTok
- FDA Accepts sNDA for ZORYVE Cream 0.3% in Children Aged 2 to 5https://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-03-in-children-ages-25/2484497/The US Food and Drug Administration (FDA) has accepted Arcutis Biotherapeutics’ supplemental New Drug Application (sNDA) seeking an expanded indication for ZORYVE® (roflumilast) cream 0.3% to include children ages 2 to 5 with plaque psoriasis.
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://practicaldermatology.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Arcutis Completes Enrollment for INTEGUMENT-INFANT Studyhttps://practicaldermatology.com/news/arcutis-completes-enrollment-for-integument-infant-study/2484474/Arcutis Biotherapeutics announced the completion of patient enrollment for the INTEGUMENT-INFANT phase 2 study, according to a press release from the company. Researchers for INTEGUMENT-INFANT will be evaluating ZORYVE® (roflum
- Report: Antibiotics Linked to Shorter Biologic Persistence in Psoriasishttps://practicaldermatology.com/news/report-antibiotics-linked-to-shorter-biologic-persistence-in-psoriasis/2484451/Antibiotic exposure is associated with reduced persistence of biologic therapies in patients with psoriasis, according to findings from a nationwide French cohort study published in JAMA Dermatology.
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- From ACAAI: Tapinarof Cream Shows Early Efficacy in Pediatric AD Regardless of Comorbiditieshttps://practicaldermatology.com/news/from-acaai-tapinarof-cream-shows-early-efficacy-in-pediatric-ad-regardless-of-comorbidities/2484383/New data from a pooled sub-analysis of the ADORING 1 and 2 trials show that VTAMA® (tapinarof) cream, 1%, was associated with improvements in children aged 2 to 17 with moderate to severe atopic dermatitis (AD). Results from th
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- FDA Approves Restylane Lyft for Chin Augmentation in Adultshttps://practicaldermatology.com/news/fda-approves-restylane-lyft-for-chin-augmentation-in-adults/2484326/Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Restylane® Lyft™ with Lidocaine for chin augmentation in adults over 21 with mild-to-moderate chin retrusion.